Nanodrugs

IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY

Absstract of: EP4613289A2

There are provided herein, inter alia, complexes, compositions and methods for the delivery of therapeutic, diagnostic and imaging agents, including nucleic acid, into a cell. The complexes, compositions and methods may facilitate complexation, protection, delivery and release of oligonucleotides and polyanionic cargos into target cells, tissues, and organs both in vitro and in vivo.

LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY

Absstract of: EP4613741A2

The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.The present invention also provides a lipid nanoparticle comprising an ionizable lipid-like compound according to Formula I and one or more RNA molecules, as well as a pharmaceutical composition or vaccine, comprising such lipid nanoparticles.

LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY

Absstract of: EP4613740A2

The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.The present invention also provides a lipid nanoparticle comprising an ionizable lipid-like compound according to Formula I and one or more RNA molecules, as well as a pharmaceutical composition or vaccine, comprising such lipid nanoparticles.

NANOPARTICLE COMPOSITIONS FOR SUSTAINED THERAPY

Absstract of: EP4613336A2

Described herein are heterodimers containing at least one first polypeptide and at least one second polypeptide, wherein the first polypeptide and the second polypeptide meet at an interface, wherein the interface of the first polypeptide contains an engineered protuberance which is positionable in an engineered cavity in the interface of the second polypeptide; and (i) the first polypeptide contains an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; or (ii) the first polypeptide contains an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof.

CHEMICAL STABILITY OF MRNA

Absstract of: WO2024097874A1

Aspects of the disclosure relate to mRNAs comprising a relatively low abundance of cytidine: adenosine (CA) dinucleotides that benefit from increased stability relative to mRNAs containing more CpA dinucleotides. The disclosure also relates to methods of modifying an mRNA sequence to improve stability. In some aspects, the disclosure relates to mRNAs comprising modified mRNA sequences with relatively reduced numbers of CpA dinucleotides, and compositions comprising mRNAs with relatively reduced numbers of CpA dinucleotides.

DEVICES AND METHODS FOR EXTRACORPOREAL CELL TREATMENT

Absstract of: AU2023374051A1

The present disclosure features a method of preparing a population of payload-associated cell complexes (PACCs), as well as related methods of use thereof.

ORAL-ADMINISTRATION-TYPE VACCINE COMPOSITION CONTAINING FIBROIN-CONTAINING NANOPARTICLES

Absstract of: EP4613287A1

A composition for an oral vaccine comprises nanoparticles containing an antigen and fibroin.

LIPOSOMES FOR ENZYMATIC DEGRADATION OF INGESTED ETHANOL

Absstract of: EP4613265A1

The present invention relates to a composition comprising a liposome and/or a polymersome, the liposome and/or the polymersome enclose an enzyme capable of degrading ethanol, wherein the liposome and/or the polymersome fulfils at least one of the following criteria (i) wherein the concentration of enzyme is above 100 U/ml composition; (ii) wherein the liposome and/or the polymersome comprises a particle size of at least 100 nm; (iii) wherein the composition is capable of degrading in the range of 50-5000 mM ethanol per hour; (iv) wherein the liposome and/or the polymersome are stable at acidic pH, such as at a pH 5.5 or below; and/or (v) wherein the pH inside the liposome and/or the polymersome is above pH 6.0.

LIPID COMPOUNDS, LIPID NANOPARTICLES, AND PHARMACEUTICAL COMPOSITIONS

Absstract of: CN120035576A

Provided herein are lipid compounds, such as compounds of Formula (I). Also provided are lipid nanoparticles and pharmaceutical compositions, each comprising a lipid compound, such as a compound of Formula (I). # imgabs0 #

SYSTEMS AND METHODS FOR MANUFACTURING LIPID NANOPARTICLES AND LIPOSOMES

Absstract of: EP4613367A1

Systems including specific arrangements of pumps, valves, and conduits, such as for mixing precursors to lipid nanoparticles to form the lipid nanoparticles, are provided. Methods of using such systems to manufacture the lipid nanoparticles are also provided.

用于表达TCRγ可变阅读框架蛋白(TARP)的癌症的新型非HLA限制性T细胞疫苗

Absstract of: AU2023364999A1

Novel compositions of TCR Gamma Alternate Reading Frame Protein (TARP) peptides combined with cationic lipids such as the DOTAP and specifically R-DOTAP, induce high levels of TARP-specific polyfunctional cytolytic T-cells. Compositions and methods of use are provided. The compositions comprise N-terminal and C-terminal overlapping peptide sequence pairs duplicating the critical central antigenic region of TARP and encompassing the entire protein selected and designed to be effectively processed by antigen-presenting cells to prime cytotoxic T cells specific for TARP-derived T cell peptide antigens when delivered in combination with immunostimulatory nanoparticles composed of R-DOTAP cationic lipids.

脂质组合物及用于递送到免疫细胞的方法

Absstract of: US2024263196A1

Provided herein, are methods, compositions, and kits for introducing a payload to an immune cell. In aspects, a lipid composition is described, which includes at least one ionizable lipid compound having the structure I. In aspects, the methods and compositions are for introducing a nucleic acid payload into immune cells, for example T cells, dendritic cells, and NK cells.

用于细胞靶向的隐形脂质纳米颗粒组合物

Absstract of: AU2023406483A1

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types,

一种转移前生态位靶向的载纳米粒髓系细胞及其制备方法和应用

Absstract of: CN120605259A

本发明公开了一种转移前生态位靶向的载纳米粒髓系细胞及其制备方法和应用，具体是合成了一种PMN微环境MMP2酶响应性的连接键，其结构不影响LNP装载ATRA药物和基因在细胞中的表达，并且在常温温和的环境下通过连接键实现AIG‑LNP在MCs细胞表面的稳定装载。

FOSL1基因在制备诱导肿瘤细胞铜死亡药物中的应用

Absstract of: CN120605346A

本发明适用于生物医药技术领域，提供了一种FOSL1基因在制备诱导肿瘤细胞铜死亡药物中的应用，其中，肿瘤为非小细胞肺癌；本发明通过靶向调控FOSL1基因表达，可以特异性诱导线粒体损伤，进而触发铜死亡。本发明基于FOSL1在辐射抗性NSCLC细胞中的差异表达及调控作用，明确FOSL1通过介导线粒体损伤、触发铜死亡、增敏放疗的核心机制，提供了一种能够诱导辐射抗性NSCLC细胞发生铜死亡的药物，以及提供了一种精准、安全、高效的肿瘤细胞辐射抗性逆转方案。

低酯化果胶在制备口服递送胰岛素的智能纳米颗粒中的应用

Absstract of: CN120605258A

本发明公开了低酯化果胶在制备口服递送胰岛素的智能纳米颗粒中的应用，包括，不同酯化度果胶的制备、亚临界水处理果胶、以及果胶基智能纳米颗粒的制备。本发明通过果胶的酯化度调控、亚临界水处理工艺以及使用合适的辅助材料，显著提高了胰岛素的包埋效率和纳米颗粒的稳定性，减少了胃肠道环境中对胰岛素的降解，提升了药物的口服生物利用度。

一种聚集诱导发光材料、纳米粒子及其制备方法与应用

Absstract of: CN120607520A

本发明涉及发光材料技术领域，公开了一种聚集诱导发光材料、纳米粒子及其制备方法与应用，所述聚集诱导发光材料的结构通式如下：#imgabs0#其中，R选自以下结构中的一种：#imgabs1#聚集诱导发光材料以吡啶基团作为受体单元，碳‑碳双键和噻吩单元作为π桥，二苯胺、双(4‑乙基苯基)胺和双(4‑(叔丁基)苯基)胺作为强电子供体。这些供体不仅提供了强大的电子供给能力，还因其高度扭曲的分子构象而成为高效的旋转子，赋予聚集诱导发光材料长发射波长和聚集诱导发光活性。

可电离脂质、其立体异构体或药学上可接受的盐、制备方法和应用

Absstract of: CN120607455A

本发明提供了一种可电离脂质、其立体异构体或药学上可接受的盐，其结构如式（Ⅰ）所述，本发明还提供了可电离脂质的制备方法和应用。本申请提供的可电离脂质可通过氢键、静电和/或疏水作用相互协作，能够稳定并保护核酸分子。在细胞内，该类可电离脂质能促进核酸的内吞并实现内涵体逃逸，从而有效促进核酸的表达。本发明提供的可电离脂质具有良好的生物相容性，并能高效地递送核酸分子，具备广泛的临床应用前景，尤其在基因治疗、细胞因子治疗和核酸疫苗开发领域中具有重要的应用价值。

Composition in the form of nanoemulsion and its use in the treatment of cancer, especially colon cancer

Absstract of: PL447923A1

Przedmiotem zgłoszenia jest innowacyjna kompozycja w postaci nanoemulsji, przeznaczona do zastosowań terapeutycznych w leczeniu raka jelita grubego. Nanoformulacja zawiera fazę olejową, którą stanowi mieszanina estrów cukrowych na bazie laktozy i bakteryjnego poli-3-R-hydroksynonanianu-koheptanianu (PHN(C9+C7)-Lak), surfaktant, który stanowi mieszanina estrów metylowych fluorowanych monomerów (PHN-O-CH2CF3 (C9+C7)), kosurfaktant, fazę wodną oraz chemoterapeutyk.

类脂质化合物及相关组合物和用途

Absstract of: WO2024155931A1

Compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications are disclosed.

一种联合金属离子的纳米蛋白药物及其制备方法和用途

Absstract of: CN120585786A

本发明属于生物医药技术领域，具体涉及一种联合金属离子的纳米蛋白药物及其制备方法和用途。本发明通过对制备方法、原料种类和用量的筛选，提供一种纳米蛋白药物。利用自组装技术，该纳米蛋白药物由包括纳米蛋白、疏水药物和铜离子的原料直接制备得到，具有药物负载率高、稳定性好、尺寸小且分布均匀等的特点，有利于临床研究的一致性和重现性；该纳米蛋白药物实现了药物的高效递送，提高了药物的生物利用度，显著提高了治疗效果。本发明的纳米蛋白药物为提高疏水药物的生物利用度和药效提供了解决方案，临床应用前景良好。

一种聚多巴胺纳米载体、制备方法及其应用

Absstract of: CN120586077A

本申请公开了一种聚多巴胺纳米载体、制备方法及其应用，聚多巴胺纳米载体包括RP‑1多肽修饰的聚多巴胺以及均匀分散在所述聚多巴胺上的Au和Gd，其中，所述RP‑1多肽的氨基酸序列为WHPWSYLWTQQA，本申请通过RP‑1修饰的聚多巴胺以及均匀分散在所述聚多巴胺上的Au和Gd，建立高效靶向胃癌细胞的纳米载体，该纳米载体可稳定负载双基因并携带双基因共转，为制备靶向胃癌制剂、逆转胃癌干细胞顺铂耐药产品以及制备抑制胃癌干细胞生长的药物提供材料。

抑制放疗后肿瘤转移纳米囊泡组合物及其制备方法与应用

Absstract of: CN120585863A

本发明公开了一种用于抑制放疗后肿瘤转移的纳米囊泡组合物，其特征在于，所述纳米囊泡为经工程化改造的细菌外膜囊泡（OS‑D），所述组合物还包含pH响应性磷脂修饰成分以及能够沉默CCDC25基因表达的小干扰RNA（siRNA）；所述siRNA通过阻断中性粒细胞外陷阱（Neutrophil Extracellular Traps，NETs）与肿瘤细胞之间的相互作用，抑制放疗诱导的NETs形成及其介导的肿瘤细胞迁移与转移，从而在放疗后实现肿瘤转移的抑制作用。本发明提供的纳米囊泡组合物能够特异性阻断肿瘤微环境中中性粒细胞外陷阱介导的肿瘤转移，以增强肿瘤术后放化疗的效果，并有效抑制肿瘤转移与复发。

一种抗帕金森的香菇外泌体制剂的制备方法及其应用

Absstract of: CN120585784A

一种抗帕金森的香菇外泌体制剂的制备方法及其应用，有效解决口服药物脑靶向递送难题。通过超速离心提取香菇的外泌体，利用亚硒酸钠、抗坏血酸等制备硒纳米颗粒，通过机械挤压法将硒纳米颗粒负载入香菇外泌体中即得抗帕金森的香菇外泌体制剂。本发明的制剂具有优秀的抗氧化效果和靶向递送能力，制备方法简单，药物效果高，具有巨大的经济和社会效益。

一种普适性的增强纤维化部位药物蓄积的单核/巨噬细胞递送系统及应用

Nº publicación: CN120585775A 05/09/2025

Applicant:

山东大学

Absstract of: CN120585775A

本发明公开了一种普适性的增强纤维化部位药物蓄积的单核/巨噬细胞递送系统及应用，包括：（1）载体的制备：将低氧响应元件HRE融合MMP14的质粒加入水相溶液中，然后与油相溶液采用微流控技术制备RMR‑LNP混悬液，提纯，然后向提纯后的体系中加入DSPE‑PEG2000‑TriArg进行孵育，获得RMR‑L‑TriArg；（2）单核/巨噬细胞的转染：将所述RMR‑L‑TriArg和单核/巨噬细胞共孵育，然后进行转染，获得增强纤维化部位药物蓄积的单核/巨噬细胞递送系统。本发明通过构建MMP14高表达的巨噬细胞能够增加向肝纤维化部位的递送，增加药物的蓄积，增强治疗效果。